费城染色体阳性急性髓性白血病（NPM1和IDH2突变）多模式疗法成功案例综合研究

IF 0.7 Q4 HEMATOLOGY Leukemia Research Reports Pub Date : 2024-01-01 DOI:10.1016/j.lrr.2024.100461

Syed Muhammad Waqar Haider , Mehwish Zehra , Nikesh N Shah , Eduardo M Sotomayor , David M Swoboda

{"title":"费城染色体阳性急性髓性白血病（NPM1和IDH2突变）多模式疗法成功案例综合研究","authors":"Syed Muhammad Waqar Haider , Mehwish Zehra , Nikesh N Shah , Eduardo M Sotomayor , David M Swoboda","doi":"10.1016/j.lrr.2024.100461","DOIUrl":null,"url":null,"abstract":"<div><p>A 67-year-old female came to Tampa General Hospital with Philadelphia chromosome-positive (Ph+) acute myeloid leukemia (AML) featuring an intriguing combination of mutations, including <em>NPM1</em> and <em>IDH2</em> mutations. Novel combination therapy with azacitidine, venetoclax and ponatinib allowed her to successfully achieve a complete response (CR) and undergo an allogeneic hematopoietic stem cell transplant (HSCT). This case report provides an overview of her clinical course, emphasizing the significance of integrated therapy and the challenges associated with balancing treatment for AML. It also underscores the importance of a multidisciplinary approach and careful monitoring of patients with complex hematologic conditions.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048924000517/pdfft?md5=2596c4784f9889a364c2caaf23574cb6&pid=1-s2.0-S2213048924000517-main.pdf","citationCount":"0","resultStr":"{\"title\":\"A comprehensive case study on successful multimodal therapy in philadelphia chromosome-positive acute myeloid leukemia with NPM1 and IDH2 mutations\",\"authors\":\"Syed Muhammad Waqar Haider , Mehwish Zehra , Nikesh N Shah , Eduardo M Sotomayor , David M Swoboda\",\"doi\":\"10.1016/j.lrr.2024.100461\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>A 67-year-old female came to Tampa General Hospital with Philadelphia chromosome-positive (Ph+) acute myeloid leukemia (AML) featuring an intriguing combination of mutations, including <em>NPM1</em> and <em>IDH2</em> mutations. Novel combination therapy with azacitidine, venetoclax and ponatinib allowed her to successfully achieve a complete response (CR) and undergo an allogeneic hematopoietic stem cell transplant (HSCT). This case report provides an overview of her clinical course, emphasizing the significance of integrated therapy and the challenges associated with balancing treatment for AML. It also underscores the importance of a multidisciplinary approach and careful monitoring of patients with complex hematologic conditions.</p></div>\",\"PeriodicalId\":38435,\"journal\":{\"name\":\"Leukemia Research Reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2213048924000517/pdfft?md5=2596c4784f9889a364c2caaf23574cb6&pid=1-s2.0-S2213048924000517-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Leukemia Research Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213048924000517\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213048924000517","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

坦帕综合医院收治了一名67岁的女性患者，她患有费城染色体阳性（Ph+）急性髓性白血病（AML），该病具有令人费解的突变组合，包括NPM1和IDH2突变。阿扎胞苷、venetoclax和泊纳替尼的新型联合疗法使她成功获得了完全缓解（CR），并接受了异基因造血干细胞移植（HSCT）。本病例报告概述了她的临床过程，强调了综合治疗的重要性以及与急性髓细胞性白血病平衡治疗相关的挑战。报告还强调了多学科方法和对复杂血液病患者进行仔细监测的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

A comprehensive case study on successful multimodal therapy in philadelphia chromosome-positive acute myeloid leukemia with NPM1 and IDH2 mutations

A 67-year-old female came to Tampa General Hospital with Philadelphia chromosome-positive (Ph+) acute myeloid leukemia (AML) featuring an intriguing combination of mutations, including NPM1 and IDH2 mutations. Novel combination therapy with azacitidine, venetoclax and ponatinib allowed her to successfully achieve a complete response (CR) and undergo an allogeneic hematopoietic stem cell transplant (HSCT). This case report provides an overview of her clinical course, emphasizing the significance of integrated therapy and the challenges associated with balancing treatment for AML. It also underscores the importance of a multidisciplinary approach and careful monitoring of patients with complex hematologic conditions.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊